What does HCL PHARMA do?

HCL PHARMA is a pharmacy in Walcourt. Private Limited, started on 6 March 2016, 2 establishments.

What is the address of HCL PHARMA?

The registered office of HCL PHARMA is located at Rue du Jardinet(Wal) 6 box 2, 5650 Walcourt.

Is HCL PHARMA still active?

Yes. According to the CBE (16 September 2026) HCL PHARMA is active, legal situation “Normale toestand”, started on 6 March 2016.

Is HCL PHARMA registered on Peppol?

Yes, HCL PHARMA is registered on the Peppol network with ID 0208:0649663933.

What is the enterprise number of HCL PHARMA?

The enterprise number of HCL PHARMA is BE0649663933.

When was HCL PHARMA founded?

HCL PHARMA was founded on 6 March 2016.

Who are the directors of HCL PHARMA?

According to the 2025 annual accounts, the directors of HCL PHARMA are: Hélène De Groote.

Is HCL PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 March 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did HCL PHARMA make in 2025?

HCL PHARMA posted a profit after taxes of € 36,408 in financial year 2025.

What is the revenue of HCL PHARMA?

As a small company, HCL PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 82,841.

HCL PHARMA (Private Limited) - Walcourt - BE0649663933

Dossier HCL PHARMA, printed on 16 September 2026 from databakkes.be/en/0649663933/hcl-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

HCL PHARMA from Walcourt, company number BE0649663933, closed financial year 2025 with a result of € 36,408 after tax. For that financial year HCL PHARMA recorded a gross margin of € 82,841 and equity of € 57,108. Compared with financial year 2024, the result moved from € 5,934 to € 36,408. Profitable, and profit is growing. The buffer shrank hard: equity is 53 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Shrank hard

€ 57,108

▼ 53% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 36,408

▲ € 30,474 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 44,170

▲ 244% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 106,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 9,111

▲ 85% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 237,787

▼ 11% vs 2024

€ 28,839 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 3,619

▲ 29% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 19,735

▲ 256% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 36,888 Gross margin 2022: € 36,888 First fiscal year in the series	€ 51,551 Gross margin 2023: € 51,551 ▲ 40% vs 2022 (€ 36,888) Favourable step	€ 43,973 Gross margin 2024: € 43,973 ▼ 15% vs 2023 (€ 51,551) Unfavourable step	€ 82,841 Gross margin 2025: € 82,841 ▲ 88% vs 2024 (€ 43,973) Favourable step	▲ 88%
Profit after taxes	€ 3,766 Profit after taxes 2022: € 3,766 First fiscal year in the series	€ 13,340 Profit after taxes 2023: € 13,340 ▲ 254% vs 2022 (€ 3,766) Favourable step	€ 5,934 Profit after taxes 2024: € 5,934 ▼ 56% vs 2023 (€ 13,340) Unfavourable step	€ 36,408 Profit after taxes 2025: € 36,408 ▲ € 30,474 vs 2024 (€ 5,934) Favourable step	▲ € 30,474
Equity	€ 101,226 Equity 2022: € 101,226 First fiscal year in the series	€ 114,566 Equity 2023: € 114,566 ▲ 13% vs 2022 (€ 101,226) Favourable step	€ 120,500 Equity 2024: € 120,500 ▲ 5% vs 2023 (€ 114,566) Favourable step	€ 57,108 Equity 2025: € 57,108 ▼ 53% vs 2024 (€ 120,500) Unfavourable step	▼ 53%
Total debts	€ 402,153 Total debts 2022: € 402,153 First fiscal year in the series	€ 385,699 Total debts 2023: € 385,699 ▼ 4% vs 2022 (€ 402,153) Favourable step	€ 365,575 Total debts 2024: € 365,575 ▼ 5% vs 2023 (€ 385,699) Favourable step	€ 445,107 Total debts 2025: € 445,107 ▲ 22% vs 2024 (€ 365,575) Unfavourable step	▲ 22%
Cash	€ 5,748 Cash 2022: € 5,748 First fiscal year in the series	€ 20,429 Cash 2023: € 20,429 ▲ 255% vs 2022 (€ 5,748) Favourable step	€ 12,852 Cash 2024: € 12,852 ▼ 37% vs 2023 (€ 20,429) Unfavourable step	€ 44,170 Cash 2025: € 44,170 ▲ 244% vs 2024 (€ 12,852) Favourable step	▲ 244%
Land & buildings	€ 317,881 Land & buildings 2022: € 317,881 First fiscal year in the series	€ 309,798 Land & buildings 2023: € 309,798 ▼ 3% vs 2022 (€ 317,881) Unchanged	€ 286,255 Land & buildings 2024: € 286,255 ▼ 8% vs 2023 (€ 309,798) Unchanged	€ 267,987 Land & buildings 2025: € 267,987 ▼ 6% vs 2024 (€ 286,255) Unchanged	▼ 6%
Retained profit	€ 88,826 Retained profit 2022: € 88,826 First fiscal year in the series	€ 102,166 Retained profit 2023: € 102,166 ▲ 15% vs 2022 (€ 88,826) Favourable step	€ 108,100 Retained profit 2024: € 108,100 ▲ 6% vs 2023 (€ 102,166) Favourable step	€ 38,508 Retained profit 2025: € 38,508 ▼ 64% vs 2024 (€ 108,100) Unfavourable step	▼ 64%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 106,000 Dividend 2025: € 106,000 Unchanged (€ 0) Unchanged
Bank debt	€ 321,946 Bank debt 2022: € 321,946 First fiscal year in the series	€ 294,276 Bank debt 2023: € 294,276 ▼ 9% vs 2022 (€ 321,946) Favourable step	€ 266,232 Bank debt 2024: € 266,232 ▼ 10% vs 2023 (€ 294,276) Favourable step	€ 237,787 Bank debt 2025: € 237,787 ▼ 11% vs 2024 (€ 266,232) Favourable step	▼ 11%
Balance sheet total	€ 503,379 Balance sheet total 2022: € 503,379 First fiscal year in the series	€ 500,265 Balance sheet total 2023: € 500,265 ▼ 1% vs 2022 (€ 503,379) Unchanged	€ 486,075 Balance sheet total 2024: € 486,075 ▼ 3% vs 2023 (€ 500,265) Unchanged	€ 502,215 Balance sheet total 2025: € 502,215 ▲ 3% vs 2024 (€ 486,075) Unchanged	▲ 3%

Key figures of HCL PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HCL PHARMA?

What happened at HCL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: profit of € 36,408 (▲ € 30,474 vs 2024). Source: NBB ↗
Mar 6, 2016 New establishment in Walcourt. KBO
Mar 6, 2016 New establishment in Walcourt. KBO
Mar 6, 2016 Start of the company according to the CBE. KBO
2016 Hélène De Groote became a director. NBB

In short

From € 3,766 profit in 2022 to € 36,408 profit in 2025.

Paid € 19,084 in corporate taxes since 2022.

Best year ever: 2025, with € 36,408 profit.

Paid out € 106,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at HCL PHARMA? We notify you, reason included.

Follow HCL PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Hélène De Groote

HCL PHARMA

Pharmacie De Groote 96%

Behind HCL PHARMA is Hélène De Groote. It owns 96% of Pharmacie De Groote itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Hélène De Groote

Director

since 2016

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Jardinet(Wal) 6 box 2

5650 Walcourt

2.253.479.056

Grand'Place(Wal) 37

5650 Walcourt

Active since 6 March 2016

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0649.663.933
VAT number: BE 0649.663.933
Registered office: Rue du Jardinet(Wal) 6 bus 2, 5650 Walcourt
Names & denominations: HCL PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 6 March 2016
Peppol: Active · Active since 20 Nov 2020
Contact: [email protected] 071611476
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗